India, Sept. 28 -- Mumbai-based Sun Pharmaceutical Industries and US-based LIB Therapeutics Inc. have announced an exclusive licensing agreement granting Sun Pharma rights to commercialise and manufacture lerodalcibep worldwide, excluding the United States and China.

Lyrokaul (lerodalcibep), a once-monthly PCSK9 inhibitor for LDL-C lowering, comes with 6-month EU ambient storage; received EU approval on September 21, 2026.

It strengthens Sun Pharma's Innovative Medicines portfolio through access to a $3.7 billion PCSK9 market Ex-US and China, growing at 38% CAGR; global PCSK9 market approaching $7 billion in 2026. LIB will receive an upfront and future milestone payments, together with royalties based on net sales in the licensed territ...